Peptide questions · VK2735
VK2735 side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for VK2735 are nausea, constipation and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: VK2735 has no label: it is still in trials.
What is commonly reported with VK2735
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Acid reflux
- Fatigue
- Dry mouth
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Acid reflux | 1: Mazdutide |
| Fatigue | 7: Semaglutide, Tirzepatide, Retatrutide, Dulaglutide and 3 more |
| Dry mouth | None: listed for VK2735 alone |

Model. Individual results vary.
Which VK2735 side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). VK2735 shares 6 of its 7 listed effects with at least one other metabolic & GLP-1 compound; dry mouth is listed for VK2735 alone.
What the VK2735 safety notes say
The library’s safety note
VK2735 has no label: it is still in trials. In the 13-week phase 2 VENTURE trial, GI side effects affected 51% to 83% across doses vs 37% on placebo, mostly mild or moderate, early, and fading over time; nausea was highest in the first week of the 15 mg group, the only one started at 5 mg instead of 2.5 mg. 9.1% stopped the drug for side effects (none on placebo), most often for nausea or vomiting. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
The library’s interaction note
No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the VK2735 reports come from
The library rates the evidence on VK2735 as moderate: animal studies plus some human data.
Of the library’s 8 research notes on VK2735, 5 rest on randomized trials, 2 on clinical data and 1 on community reports.
Our 1 study page on VK2735: 1 randomized trial.
So VK2735 has controlled trials in people to set its listed effects against.
What our VK2735 study pages report on safety
VK2735: up to 14.7% weight loss at 13 weeks in VENTURE
Randomized trial, human, 2026: The most common side effects involved the stomach and gut, and people reported them less often once the dose had been stepped up and held steady. Every dose of VK2735 in this phase 2 trial led to weight loss over 13 weeks, and gut-related side effects were the main issue, reported less often as treatment went on.
Questions people ask
What are the side effects of VK2735?
The side effects most commonly reported for VK2735 are nausea, constipation and diarrhea, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do VK2735’s side effects come from human studies?
The library rates the evidence on VK2735 as moderate, and the library’s evidence on it includes controlled trials in people.
Which VK2735 side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists dry mouth for VK2735 alone.
Does VK2735 interact with other medicines?
The library’s interaction note on VK2735 begins: No interaction studies have been published.